Laura M Juliano1, Roland R Griffiths. 1. Department of Psychology, American University, 4400 Massachusetts Avenue, Washington, DC 20016, USA.
Abstract
RATIONALE: Although reports of caffeine withdrawal in the medical literature date back more than 170 years, the most rigorous experimental investigations of the phenomenon have been conducted only recently. OBJECTIVES: The purpose of this paper is to provide a comprehensive review and analysis of the literature regarding human caffeine withdrawal to empirically validate specific symptoms and signs, and to appraise important features of the syndrome. METHODS: A literature search identified 57 experimental and 9 survey studies on caffeine withdrawal that met inclusion criteria. The methodological features of each study were examined to assess the validity of the effects. RESULTS: Of 49 symptom categories identified, the following 10 fulfilled validity criteria: headache, fatigue, decreased energy/activeness, decreased alertness, drowsiness, decreased contentedness, depressed mood, difficulty concentrating, irritability, and foggy/not clearheaded. In addition, flu-like symptoms, nausea/vomiting, and muscle pain/stiffness were judged likely to represent valid symptom categories. In experimental studies, the incidence of headache was 50% and the incidence of clinically significant distress or functional impairment was 13%. Typically, onset of symptoms occurred 12-24 h after abstinence, with peak intensity at 20-51 h, and for a duration of 2-9 days. In general, the incidence or severity of symptoms increased with increases in daily dose; abstinence from doses as low as 100 mg/day produced symptoms. Research is reviewed indicating that expectancies are not a prime determinant of caffeine withdrawal and that avoidance of withdrawal symptoms plays a central role in habitual caffeine consumption. CONCLUSIONS: The caffeine-withdrawal syndrome has been well characterized and there is sufficient empirical evidence to warrant inclusion of caffeine withdrawal as a disorder in the DSM and revision of diagnostic criteria in the ICD.
RATIONALE: Although reports of caffeine withdrawal in the medical literature date back more than 170 years, the most rigorous experimental investigations of the phenomenon have been conducted only recently. OBJECTIVES: The purpose of this paper is to provide a comprehensive review and analysis of the literature regarding humancaffeine withdrawal to empirically validate specific symptoms and signs, and to appraise important features of the syndrome. METHODS: A literature search identified 57 experimental and 9 survey studies on caffeine withdrawal that met inclusion criteria. The methodological features of each study were examined to assess the validity of the effects. RESULTS: Of 49 symptom categories identified, the following 10 fulfilled validity criteria: headache, fatigue, decreased energy/activeness, decreased alertness, drowsiness, decreased contentedness, depressed mood, difficulty concentrating, irritability, and foggy/not clearheaded. In addition, flu-like symptoms, nausea/vomiting, and muscle pain/stiffness were judged likely to represent valid symptom categories. In experimental studies, the incidence of headache was 50% and the incidence of clinically significant distress or functional impairment was 13%. Typically, onset of symptoms occurred 12-24 h after abstinence, with peak intensity at 20-51 h, and for a duration of 2-9 days. In general, the incidence or severity of symptoms increased with increases in daily dose; abstinence from doses as low as 100 mg/day produced symptoms. Research is reviewed indicating that expectancies are not a prime determinant of caffeine withdrawal and that avoidance of withdrawal symptoms plays a central role in habitual caffeine consumption. CONCLUSIONS: The caffeine-withdrawal syndrome has been well characterized and there is sufficient empirical evidence to warrant inclusion of caffeine withdrawal as a disorder in the DSM and revision of diagnostic criteria in the ICD.
Authors: R R Griffiths; S M Evans; S J Heishman; K L Preston; C A Sannerud; B Wolf; P P Woodson Journal: J Pharmacol Exp Ther Date: 1990-12 Impact factor: 4.030
Authors: Marcelo E Bigal; Fred D Sheftell; Alan M Rapoport; Stewart J Tepper; Richard B Lipton Journal: Headache Date: 2002 Jul-Aug Impact factor: 5.887
Authors: Marina Roizenblatt; Vitor Dias Gomes Barrios Marin; Alex Treiger Grupenmacher; Felipe Muralha; Jean Faber; Kim Jiramongkolchai; Peter Louis Gehlbach; Michel Eid Farah; Rubens Belfort; Mauricio Maia Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389
Authors: Martin R Yeomans; Shabnam Javaherian; Heather M Tovey; Lorenzo D Stafford Journal: Psychopharmacology (Berl) Date: 2005-10-12 Impact factor: 4.530